Lillys – Instametta

What’s behind Eli Lilly’s down-and-up day after last week’s surge

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time…

You probably already know that pharmaceutical powerhouses Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) dominate the anti-obesity drug…

Lilly’s new GLP-1 pill had 1,390 prescriptions in its first week on the market. www.marketwatch.com #Lillys #GLP1 #pill #robust #start

Eli Lilly and Company (NYSE:LLY) is among the stocks in focus, as Jim Cramer analyzed the broader market impact of…

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity…

Scooping up Centessa gives Lilly a foothold in narcolepsy and a promising new class of wakefulness drugs. www.bloomberg.com #Lillys #Billion #Bet…

In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair of headlines…

Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug…

Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant…

Eli Lilly’s oral GLP-1 candidate, orforglipron, won’t earn approval as fast as the company expected. Meanwhile, a notable competitor is…